Seer Inc Ordinary Shares - Class A SEER
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
The Radoff-JEC Group Calls on Seer Inc. and Its Advisors to Reevaluate Its Premium Acquisition Proposal in the Best Interests of All Stockholders
-
The Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.
-
The Radoff-JEC Group Responds to Seer, Inc.’s Rejection of April 24th Acquisition Proposal
-
The Radoff-JEC Group Submits Improved Non-Binding Proposal to Acquire Seer, Inc.
-
The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.
Trading Information
- Previous Close Price
- $1.69
- Day Range
- $1.67–1.74
- 52-Week Range
- $1.65–2.41
- Bid/Ask
- $1.69 / $1.74
- Shares Outstanding
- 54.98M
- Market Cap
- $92.92M
- Volume/Avg
- 78,673 / 345,828
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 13.07%
Company Profile
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 124
- Website
- https://www.seer.bio
Valuation
|
Metric
|
SEER
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.39 |
Price/Sales | 6.52 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SEER
|
|---|---|
Quick Ratio | 16.69 |
Current Ratio | 17.73 |
Interest Coverage | — |
Quick Ratio
SEER
Profitability
|
Metric
|
SEER
|
|---|---|
Return on Assets (Normalized) | −19.43% |
Return on Equity (Normalized) | −21.90% |
Return on Invested Capital (Normalized) | −22.91% |
Return on Assets
SEER
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Tbtrmdx | Yffqwl | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hyzmpdmd | Nnstcm | $65B | |||
| argenx SE ADR
ARGX
| Cdsynnf | Jcnw | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tcjxckfm | Fxjtp | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Zmfzzfysp | Mpxscl | $25B | |||
| BioNTech SE ADR
BNTX
| Drqfqsdw | Lllfs | $22B | |||
| Incyte Corp
INCY
| Xmgrgcsr | Mqnh | $21B | |||
| Moderna Inc
MRNA
| Pwfpqyxk | Hvxhp | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Hsxrjfkx | Cpmk | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Dtcxyydh | Fscp | $13B |
United States